Glenmark Pharma Recommends 250% Dividend; FY26 Results

Glenmark Pharmaceuticals Ltd's Board of Directors approved the audited financial results for the quarter and year ended March 31, 2026. They recommended a dividend of 250% (₹2.5 per share) on the equity share capital of the company, subject to shareholder approval. The Board meeting, held on May 29, 2026, reviewed the financial performance, with results available on the company website. Standalone revenue from operations for the year ended March 31, 2026, was ₹84,400.99 million compared to ₹92,264.09 million in the previous year. The company reported a standalone loss after tax of ₹2,007.99 million for the year ended March 31, 2026, compared to a profit of ₹16,103.50 million in the previous year.